Observational Registry of Treatment Patterns in Castrate-resistant Prostate Cancer (CRPC) Patients

Observational Prospective Study of Survival, Treatment Patterns, Disease and Economic Outcomes in Patients With Metastatic Castrate-resistant Prostate Cancer (CRPC) With Progression During or After a First-line Docetaxel-based Regimen

Primary Objective:

• Describe real-life survival of CRPC patients who received first-line docetaxel and have disease progression

Secondary Objective:

• Describe treatment patterns
• Describe the characteristics and outcomes of patients who received second-line taxane-based treatment compared to others
• Describe economic and patient-reported outcomes

Inclusion criteria:

• Patients with CRPC progressing during the course of first line docetaxel-based chemotherapy or after at least 3 cycles (equivalent to 225mg/m2) of first line docetaxel-based chemotherapy
• Patient who have given their written consent

Exclusion criteria:

• Current participation in a clinical trial for the second-line treatment of prostate cancer
• Patients having received less than 3 cycles of first line docetaxel-based chemotherapy and discontinued for a reason other than disease progression or toxicity
• Patients having already started a second line treatment

The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.